Viemed(US:VMD)2026-03-04 21:50Financial Performance - For the year ended December 31, 2025, Viemed generated revenues of $270.3 million, a 20.5% increase from $224.3 million in 2024, with net income rising to $15.4 million from $11.4 million[191]. - For the year ended December 31, 2025, total revenue was $270.3 million, an increase of $46.0 million (20.5%) compared to 2024[210]. - Net income for the year ended December 31, 2025, was $15.4 million, reflecting a $4.0 million (34.8%) increase from 2024, with a net income margin of 5.7%[225]. - Net income for 2025 was $15,376,000, an increase of 34.5% from $11,409,000 in 2024 and 50.5% from $10,243,000 in 2023[268]. - The company achieved a net income of $15.4 million in 2025, up 35.5% from $11.4 million in 2024[264]. - Basic earnings per share for 2025 was $0.38, compared to $0.29 in 2024 and $0.27 in 2023[379]. - The diluted earnings per share for 2025 was $0.37, an increase from $0.28 in 2024 and $0.25 in 2023[379]. Revenue Breakdown - Revenue from the rental and sale of home medical equipment accounted for 90.8% of total revenue in 2025, compared to 91.0% in 2024[191]. - Ventilator rentals represented 50.6% of total revenue in 2025, down from 55.6% in 2024[187]. - Ventilator rental revenue increased by $12.2 million (9.8%) in 2025, driven by higher patient volumes and demand for ventilation services[211]. - Equipment and supply sales revenue surged by $19.4 million (62.7%), largely due to the success of the sleep resupply program and maternal health offerings from the Lehan acquisition[211]. - Revenue from Medicare as a percentage of total revenue decreased to 38% in 2025 from 41% in 2024 and 44% in 2023[298]. Operational Metrics - The company employed 401 licensed respiratory therapists (RTs) as of December 31, 2025, representing approximately 29% of the total workforce[188]. - The number of active ventilator patients at the end of Q4 2025 was 12,259, a slight decrease from 12,372 in Q3 2025[205]. - Viemed's adjusted EBITDA for Q4 2025 was $18.2 million, an increase from $16.1 million in Q3 2025[205]. - The company expects continued growth and improved operating efficiencies, although gross margin may fluctuate based on revenue mix changes[214]. Expenses and Costs - Selling, general and administrative expenses totaled $121.4 million, an increase of $15.2 million (14.3%) from 2024, but as a percentage of revenue improved to 44.9%[215]. - Research and development costs were $3.0 million, a slight decrease of $0.1 million (1.7%) from 2024, with expectations to remain consistent in 2026[218]. - Stock-based compensation increased to $9.1 million, up $2.8 million (45.3%) from 2024, reflecting a focus on employee retention and long-term incentives[219]. - Interest expense for 2025 was $1.2 million, an increase of $0.4 million from 2024, primarily due to debt issued for the Lehan acquisition[223]. Cash Flow and Liquidity - Cash and cash equivalents decreased to $13.5 million as of December 31, 2025, down from $17.5 million at the end of 2024[229]. - Net cash provided by operating activities for the year ended December 31, 2025 was $51.916 million, compared to $39.089 million in 2024, marking a 33% increase[231]. - Net cash used in investing activities for 2025 was $50.166 million, primarily due to the acquisition of Lehan for $26.3 million and capital expenditures of $23.8 million[234]. - The company’s principal source of liquidity is operating cash flow, supplemented by amounts available under the 2022 Senior Credit Facilities[238]. Acquisitions and Goodwill - The Company completed the acquisition of Lehan Drugs, Inc. on July 1, 2025, for a total consideration of approximately $29.2 million, resulting in goodwill of $25.9 million[316][317]. - Goodwill recognized from the acquisition of Lehan primarily represents expected operational synergies and strategic geographic expansion across the Midwest[319]. - The acquisition of Home Medical Products, Inc. on June 1, 2023, involved a cash payment of approximately $29 million, leading to goodwill of $29.8 million[321][322]. Assets and Liabilities - Total assets increased to $199.2 million in 2025 from $177.1 million in 2024, reflecting a growth of 12.5%[262]. - The company’s total liabilities increased to $55.6 million in 2025 from $43.8 million in 2024, marking a 26.9% rise[262]. - Total accrued liabilities rose to $23.9 million as of December 31, 2025, compared to $20.2 million in 2024[325]. - The Company’s debt under the 2022 Senior Credit Facilities increased to $12.9 million as of December 31, 2025, from $4.6 million in 2024[326]. Taxation - The Company recognized a provision for income taxes of $6.391 million for the year ended December 31, 2025, compared to $4.761 million in 2024 and $4.148 million in 2023[372]. - The effective tax rate for the Company was 29.4% for the years ended December 31, 2025 and 2024, and 28.8% for 2023[370]. - Total income taxes paid for the year ended December 31, 2025, amounted to $7,390 million, an increase from $6,827 million in 2024 and $3,566 million in 2023[374]. Stock and Share Repurchase - The company repurchased 1,976,441 common shares under the 2025 Share Repurchase Program, totaling $13.2 million[230]. - The Company authorized a share repurchase program on March 4, 2026, allowing for the repurchase of up to 1,930,131 shares effective through March 2027[380]. - The share repurchase program does not obligate the Company to acquire any specific number of shares and may be modified or discontinued at the Company's discretion[381].